Kaila T, Salminen L, Huupponen R
Department of Pharmacology, University of Turku, Finland.
J Ocul Pharmacol. 1985 Spring;1(1):79-83. doi: 10.1089/jop.1985.1.79.
Symptoms and findings arising from the systemic beta blockade caused by topical ocularly applied timolol appear shortly after drug application. We studied the systemic absorption of 20 microliters of 0.5% timolol instilled unilaterally in the lower conjunctival cul-de-sac in 6 volunteers. At 3 min one subject, at 5 min three and at 8 min all but one showed measurable (greater than or equal to 215 pg/ml) timolol concentrations in the plasma. The rapid systemic absorption of topically applied ocular timolol observed in our study is consistent with the rapid appearance of the cardiovascular and pulmonary side effects reported in connection with timolol eye drop therapy.
局部眼部应用噻吗洛尔引起的全身β受体阻滞症状和体征在用药后不久就会出现。我们研究了6名志愿者单侧下结膜穹窿部滴入20微升0.5%噻吗洛尔后的全身吸收情况。3分钟时1名受试者、5分钟时3名受试者以及8分钟时除1名受试者外的所有受试者血浆中噻吗洛尔浓度均可测(大于或等于215皮克/毫升)。我们研究中观察到的局部应用眼部噻吗洛尔的快速全身吸收与噻吗洛尔滴眼液治疗相关报道的心血管和肺部副作用的快速出现一致。